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Pathophysiology of hormone-resistant  
prostate cancer
Abstract
Androgen-deprivation therapy (ADT) has been for many years the cor-
nerstone of metastatic prostate carcinoma (PC) treatment. It is very well 
documented that the majority of cancer cells in prostate gland remain an-
drogen responsive what was the basis for androgen suppression in treatment. 
Nevertheless, after some time or sometimes initially, PCa cells become resis-
tant to castration serum level of testosteron, because of some genetic and 
epigenetic changes that make them independent from hormone activation. 
There are two therories – the clonal theory and the adaptation theory of how 
some carcinoma cells become castration-resistant. It has been shown re-
cently, that PCa cells can still use androgen receptor as a major signaling 
pathway, by activation of enzyme machinery or de novo production of an-
drogen within the cells.
IntroductIon
Prostate cancer is the second most common cancer in male in Croa-tia and the third most common cause of death by cancer (Figure 1) 
(1). In many western countries due to earlier detection and widely used 
PSA in screening, prostate cancer became the most common cancer in 
male. Although a great progress has been achieved in the last two de-
cades regarding screening, early detection and treatment, a large number 
number of patients eventually have advanced (metastatic) disease. One 
of the most crucial discoveries in the area of hormone treatment of tu-
mors generally was the one of Charles Huggins. Owing to his work we 
understood androgen deprivation in prostate cancer which became the 
cornerstone of hormonal treatment until nowdays (2). Nevertheless, it 
was indicative the comment dr Huggins put in his Nobel Prize lecture 
in 1966: „....it is obvious that there are many failures of endocrine therapy 
to control the disease“. Today, it is very well known and experienced that 
despite inducing a regression of a large magnitude, androgen deprivation 
therapy (ADT) is usually followed by regrowth of the tumor. This phe-
nomenon is known as androgen independence (AI) or, recently, the term 
castration resistance prostate cancer has been introduced (CRPC) (3).
Initially, the progression of prostate cancer in castration setting was 
not clearly understood. However, two different theories have emerged 
to explain the mechanism by which prostate cancer cells become andro-
gen-insensitive. The first one is assuming the existence of pre-existing 
clones of CRPC cells that escape any hormonal manipulation at any 
time (clonal selection theory); the second theory, known as adaptive the-
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ory, postulates the existence of subsequent phases of up- 
and downregulation or mutations of important genes that 
enable cancer cells to survive and/or regrow after ADT. 
We are aware that these two theories coexist in prostate 
cancer patients (Figure 2) (4).
Androgen dependence of normal and 
cancerous epithelial cells
The growth and maturation of the normal prostate is 
dependent on the secretion of androgen by testis. The 
normal prostatic epithelium is made of different compart-
ments, with different levels of AR expression and therefore 
different sensitivities to androgens (5). Embryonically, 
prostate develops from the male urogenital sinus under 
the stimulation of androgen. This process is under con-
troll of tumor stroma.
Androgen receptors (Ars)
The regulatory effect of androgens is mediated through 
the androgen receptor (AR). AR is located on X chromo-
some, spanning about 180 kD od DNA, and is a member 
of the nuclear steroid hormone receptor super family. It 
Figure 1. Estimated mortality and prevalence of cancers for men in Croatia, 2012 (EUCAN).
Figure 2. Two theories explaining mechanisms of CRPC-cells.
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consists of 4 domains: N-terminal domain (NTD), a 
highly conserved DNA-binding domain (DBD), a short 
hinge region and a moderately conserved C-terminal do-
main, the ligand-binding domain (LBD) (6). The DBD 
contains a classical two zinc-finger motif allowing recog-
nition and binding to specific DNA sequences known as 
Androgen Response Elements (AREs). The binding of the 
AR to AREs allows the recruitment of AR co-activators 
and/or co-repressors that regulate the transcriptional ma-
chinery by direct physical interaction with general tran-
scription factors and RNA polymerase, by facilitating AR/
ARE binding and chromatin remodelling, and by chang-
ing AR folding and AR subcellular localisation (7).
regulation of normal epithelium by 
androgens
A specific subset of smooth muscle cells expressed both 
the 5a-reductase (5AR) enzyme and the AR. The 5AR 
transforms the low level of cirulating testosteron (T) into 
dyhidrotestosteron (DHT), which stimulates the AR 10 
times more than T. DHT binding to the AR stimulates 
the secretion of paracrine and autocrine growth factors, 
known as andromedins, such as IGF-1, FGF-7 and -10, 
and VEGF. These andromedins activate the formation of 
blood vessels and the maturation of undifferentiated epi-
thelium into a simple stratified glandular circular epithe-
lium composed of a basal layer of cuboidal cells making 
the epithelial components of the basement membrane 
separating the epithelium from the stroma. A second 
layer of columnar secretory-luminal cells forming a glan-
dular lumen is attached to these basal cells. During pu-
berty, under the T serum rise, prostate is maturing into 
its definitive architecture. After that, because of reciprocal 
positive feedback loop between stromal and epithelium 
cells, the epitelial compartment enters a steady-state 
maintanance phase in which the rate of epithelial prolif-
eration balances the rate of death, such that neither over-
growth nor regression of the gland normally occurs (8).
Different levels of AR expression and therefore differ-
ent sensitivities to androgens exist in normal prostate 
epithelium. Prostate adult stem cells (PAS) are present in 
the very small proportion (less than 5%), constituing 
basal compartment directly separated from the stromal 
compartment. Nearby, there are also transit-amplifying 
(TA) cells which are progenitor cell type that undergoes 
a limited number of proliferative replications before ter-
minal differentiation. As in the case of PSA, TA cells do 
not express AR and are dependent on andromedins pro-
duced by stromal cells. After a limited lumber of cell divi-
sions, TA cells mature into intermediate cells that express 
cytokeratins 5, 8, 15 and 18, Prostate Stem Cell Antigen 
(PSCA), and AR mRNA, but not yet AR protein. Inter-
mediate cells are migrating in the luminal-secretory layer. 
In these cells, AR activation promotes differentiation int 
secretory cells that will produce prostate-specific antigen 
(PSA) and other secretion products. AR activation plays, 
unexpectedly, anti proliferative role in these luminal-se-
cretory cells, by upregulating expression of cyclin-depen-
dent kinase inhibitors p21 and p27. Thus, luminal secre-
tory-cells represent the terminal stage of maturation of 
hierarchical expanding stem cell units and are quantita-
tively far the major epithelial genotype in the gland, even 
though they are non-proliferating.
There has been an intense search to identify the spe-
cific epithelial cell subtype in which the initial carcino-
genic process could initiate. In two common prostate 
cancer-precursors, high-grade PIN and prostatic inflam-
Figure 3. Mechanisms of castration-resistance.
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matory atrophy (PIA), high levels of AR have been found 
(9). That means, obviously, that AR is during early phase 
of carcinogenesis converted from a growth suppressor 
gene to an oncogene. As the consequence, AR-gain-of-
function allows activation of different molecular signaling 
pathways stimulating the proliferation and survival of 
these initiated prostatic cells directly (10).
Physiological basis of androgen 
suppression
In normal physiologic conditions, prostatic cell prolife-
ration is balanced by an equal rate of prostatic cell death 
such that neither involution nor overgrowth of the gland 
my occur with time. Following castration, there is rapid 
decrease of serum T below critical value resulting in loss 
in the glandular epithelial cells that are androgen depen-
dent and undergo apoptosis (11). By 12 to 24 hours post-
castration, the intracellular DHT levels are about 5% of 
normal, leading to changes in nuclear AR function. This 
mechanisms is based on stromal-epithelial interactions 
since it requires paracrine activity of stromal AR, thus 
leading to decrease of andromedins below critical level 
(12). Some of andromedins are explained as modulators 
of DHT-dependent survival, such as the keratinocyte 
growth factor (KGF), and transformin growth factor b-1 
(TGF b-1) (13,14). Once levels of andromedins decrease 
below critical level, apoptosis is activated. Some authors 
demonstrated that the apoptosis is activated in prostate 
cancer cells, even if they are not proliferating. On the 
other side, in PC cells that are AR-independent apoptosis 
can not be activated (15).
How do cells progress in a low 
testosterone environment?
The phenomenon named hormone resistance or andro-
gen independence, nowdays used term castration resis-
tance, means the loss of ADT effect after certain time, in 
the absence of circulating androgen. It was already de-
scribed by Huggins, and today this term include two dif-
ferent clinical scenarios. One includes „adaption“ model, 
which means that CRPC cells arise through genetic/epi-
genetic conversion of previously androgen dependent cells 
during conditions of ADT. The alternative model is 
known as „clonal selection“, suggesting proliferation of 
quiscent population of rare castration-resistant cells with-
in an otherwise androgen.dependent tumor. We know 
that progression to CRPC is a very heterogeneous process 
between patients and within a patient’s own cancer. There 
are many changes in protein and gene regulation that in 
part might explain the complex process of castration re-
sistance (Figure 3).
the clonal theory
There are evidences that ADT induces selective out-
growth of aggressive hormone-refractory PCa clones ex-
pressing distinct cellular and molecular properties not 
present in parental androgen-dependent cancer cells (16).
A pool of androgen-independent cells. CRPC may origi-
nate from a long-term resident pool of PSA cells and TA 
cells that are insensitive to AR pathways. The cancer stem 
cell model is consistent with the observed phenotypic het-
erogeneity found in many tumors, including prostate 
adenocarcinoma. Specific features of neuroendocrine car-
cinoma could be also explained in that sense. Neuroen-
docrine cells are rare and originate from PAS or interme-
diate cells located in the luminal layer of the epithelium 
together with the secretory cells (17). Neuroendocrine 
cells produce a number of growth factors, including sero-
tonin and bombesin, which promote the growth via para-
crine mechanisms. Neuroendocrine cells are AR indepen-
dent and there is no apoptosis induced by ADT (18).
Acquired mutations in androgen-dependent PCa cells to 
become androgen-independent. During the process of car-
cinogenesis, CRPC clones may appear from acquired 
mutations. There are many pathways to be involved in 
such mechanism, like TMPRSS2-ETS rearrangements, 
PI3K/AKT/PTEN pathways, and BCL-2.
PI3K/AKT/PTEN pathway has been implicated in 
CRPC. PI3K are involved in the phosphorylation of 
membrane inositol lipids, mediating cellular signal trans-
duction (19). One of the most important downstream 
proteins is mTORcomplex 1, a serine/threonine kinase 
that plays a critical role in protein synthesis, angiogenesis, 
and cell cycle progression. AKT is negatively regulated by 
tumor suppressor protein PTEN, which dephosphorylates 
PIP3. Several observations suggest that PI3K/AKT/
PTEN signaling pathways are playing an important role 
in CRPC by helping cells to maintain continued prolif-
eration in low-androgen environments. Functional loss of 
PTEN is associated with increased AKT-1 phosphoryla-
tion and appears to be involved in resistance to castration 
(20). Immunohistochemical studies have indicated a loss 
of PTEN expression in 79% of CRPC samples (21). Fur-
thermore, about 30% of the chemo-naive patients and 
24% of the chemo-resistant patients had homozygous or 
heterozygous loss of PTEN (22).
BCL-2 in an antiapoptotic gene, and its overexpression 
might mediate development of CRPC. It is expressed in 
CRPC, but usually not in secretary prostate epithelial 
cells. Some IHC studies demonstrated increased BCL-2 
expression in CRPC specimens compared to hormone-
naive prostate cancer tissues (23).
the adaptation theory and the role 
of Ar
The most important argument in favour of the „adap-
tation“ model is the evidence of retention of AR signaling 
in CRPC. Even when PCa progresses to CRPC, AR ac-
tivation and signaling remains sustained through a variety 
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of mechanisms (24, 25). Several mechanisms have been 
proposed to explain the reactivation of an AR-dependent 
pathway: amplification of AR gene copy, gain-of-function 
mutations of AR, deregulation of the AR/co-regulator/
co-respressor control, intracellular steroidogenesis and 
ligand-dependent activation of AR.
Amplification of AR gene. Amplification of AR-gene 
copy number means higher sensitivity and responsiveness 
to low levels of circulating or intracellular androgens, re-
sulting in survival and growth advantage upon castration. 
It is seen in about 30% of CRPC (26). It is more likely 
that cells with an AR gene amplification will respond to 
ADH several times better after progressing. It is also in-
teresting, that increased AR levels can convert an antian-
drogen from na AR antagonist to an AR agonist, what is 
known mechanism of antiandrogen-withdrawal response 
(27, 28).
Gain-of-function mutations of AR. Several mutations 
have been identified that may confer increased AR protein 
stability, greater sensitivity to androgens, aberrant re-
sponses to antiandrogens or other steroid hormones, li-
gand-independent activity, or increased recruitment of 
AR co-activator proteins (29). In some cases, mutated AR 
may lack the entire LBD, leading to an auto-activated 
mutant that mediates AR signaling independent of any 
ligands. That means, that such an AR can be constitu-
tively active (30).
Deregulation of the AR/co-regulator/co-respressor. Some 
ligands can affect receptor activity at the transcriptional 
level, with subsequent effects on target gene regulation. 
AR overexpression increases the expression of androgen-
stimulated co-activators such as MAK, BRCA1, AIB1, or 
CB (29).
Intracellular steroidogenesis. One of the most exciting 
observations in the last several years is the ability of 
CRPC to synthesise androgen de novo or convert adrenal 
androgens into T and DHT by expressing or up-regulat-
ing steroidogenic enzymes including CYP17A1, HSD3B1, 
CYP19A1. It was observed almost 30 years ago that ad-
renal androgenes could induce AR signaling after intra-
prostatic conversion despite low levels of circulating tes-
tosterone (31, 32). It was also discovered that CRPC cells 
were capable of synthetising de novo androgens from 
membranes’ cholesterol molecules. T levels within metas-
tases can be several times higher than levels in the pri-
mary untreated PCa (33).
Ligand-dependent activation of AR. The activation of 
different signal transduction pathways in CRPC cells can 
enhance the activity of the AR or its co-activators in the 
presence of low levels or even in the absence of androgens. 
In CRPC there are many molecules overexpressed leading 
to AR stimulation – for example, IL-6, KGF, EGF, IGF-
1 etc. (34).
conclusIon
CRPC is one of the greatest challenges in the treat-
ment of advanced prostate cancer. Although ADT is still 
the golden standard of the treatment of PCa, treatment 
paradigm is changing due to new insights in pathophysi-
ology of prostate cancer. Today, we already use our knowl-
edge of AR-active signaling pathway even after progress-
ing prostate cancer, in treatment prostate cancer patients, 
before or after chemotherapy. In the future, hopefully, 
we’ll be able to inhibit growth of prostate cancer cells 
based on more individual base than it is nowdays.
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